Viatris
VTRS · What the business does, what can go wrong, and how options sellers approach it
What it does
Viatris is a global pharmaceutical company formed by the combination of Upjohn, Pfizer's off-patent drug business, and Mylan, a large generic drug maker. It sells medicines in a wide range of countries and therapeutic areas.
Its portfolio includes generic drugs, biosimilars (lower-cost versions of complex biologic medicines), and well-known older brands such as Lipitor, Norvasc, Lyrica and Viagra.
How it makes money
Viatris sells prescription medicines to pharmacies, wholesalers, hospitals and health systems. Revenue comes from two broad groups: generics and biosimilars, which compete on price and reliability of supply, and established brands, which benefit from name recognition and physician familiarity even after patent protection has ended.
Manufacturing scale and a broad product range help the company spread costs and serve large customers.
Why investors own it
Investors often view Viatris as a mature, cash-generating healthcare business. Demand for medicines tends to be steady across economic cycles, and the company's geographic spread reduces reliance on any one market. Some investors are drawn to the possibility of cash returns to shareholders and to the potential for new products to offset declines in older ones. None of this is guaranteed.
What can go wrong
- Generic drug pricing is competitive, and price erosion can squeeze margins.
- Older brands can lose sales as cheaper alternatives arrive.
- Manufacturing problems or regulatory actions can disrupt supply and add costs.
- Government pricing policies and healthcare reform can reduce what drugs earn.
- Debt taken on to build the company can limit flexibility.
- Litigation is a recurring risk across the pharmaceutical industry.
- Currency swings affect results because sales are international.
What to watch
- Organic revenue trends in generics versus brands
- Progress of new product launches and the development pipeline
- Gross and operating margins
- Free cash flow and debt reduction
- Regulatory inspections and approvals
- Pricing developments in the U.S. and other major markets
- Capital allocation decisions, including dividends and buybacks
Options income angle
Options on VTRS are generally available across a range of strikes and expirations, though trading is usually lighter than for the largest healthcare names, so bid-ask spreads can be wider on less popular contracts. Implied volatility tends to rise around quarterly earnings, guidance changes, pipeline or regulatory news, and shifts in drug pricing policy. Selling premium, through covered calls or cash-secured puts, can generate income, but a sharp move on company news can lead to losses on the stock position or cap upside well below the market's gains. Check liquidity and the earnings calendar before selling options.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Viatris reported a net loss of $3,514.9 million for the year, driven mainly by a goodwill impairment charge of $2.94 billion and a loss on its Biocon Biologics stake. Revenue fell as divested businesses dropped out and an FDA problem at an Indian plant hurt sales. The company has launched a restructuring program with up to approximately 10% workforce cuts, and its debt, regulatory exposure and customer concentration remain the main pressure points.
How the business did
- Total revenues were $14,299.9 million, down from $14,739.3 million. Net loss was $3,514.9 million, against $634.2 million the year before. Diluted loss per share was $3.00.
- Excluding divestitures, base business erosion was approximately $465.8 million, of which approximately $370 million came from the "Indore Impact" (an FDA warning letter and import alert at the Indore, India plant). New product sales of approximately $323.7 million partly offset this.
- Greater China net sales rose 8%, helped by e-commerce, retail and private hospitals. JANZ (Japan, Australia, New Zealand) fell 11% on government price cuts and added competition. Developed Markets fell 5% and Emerging Markets fell 2%.
- Adjusted EBITDA, a profit measure that strips out one-off and non-cash items, was $4,160.0 million versus $4,669.4 million. Adjusted EPS was $2.35 versus $2.65.
- Operating cash flow was $2.32 billion. The company paid $561.2 million in dividends and spent $500.5 million on share repurchases.
Risks specific to this company
- Indore plant: The warning letter and import alert restrict 11 products from entering the U.S. and have hurt sales in other regions. The company says it may not recover the lost revenue, and it expects the plant to be ready for FDA reinspection in 2026.
- Nashik plant fire: A fire in February 2026 suspended manufacturing at another Indian facility. The company expects to resume in April 2026 and relies on insurance for losses.
- Customer and product concentration: The top three customers made up approximately 25% of net sales and the top ten products approximately 36%.
- Drug pricing pressure: In China, volume-based procurement (competitive bidding) has led some bidders to cut prices by as much as 96%. The company has lost bids there. U.S. Medicare reforms and tender systems in other countries add pressure.
- Debt and impairments: Credit facilities require a Maximum Leverage Ratio of 3.75 to 1.00, and approximately $259 million of debt carries floating rates. Further goodwill impairments are possible, and Greater China's estimated value exceeded its book value by only approximately $322.0 million or 5.8%.
- Legal exposure: The company has approximately $535 million accrued for legal contingencies. It must also pay Pfizer 57% of certain opioid-related losses.
What management is watching
- Restructuring: The enterprise-wide strategic review led to a program expected to cost between $700 million and $850 million before tax. Management expects savings between $600 million and $700 million once fully in place, mostly over the next three years.
- Pipeline and business development: Management is funding the selatogrel and cenerimod Phase 3 programs, which raised R&D expense to $965.9 million. It also bought Aculys Pharma and expects regulatory responses in 2026 on a contraceptive patch and a fast-absorbing meloxicam.
- Biocon Biologics sale: The company sold its stake for $815 million, made up of $400 million in cash and $415 million in Biocon shares under a six-month lock-up. The deal closed in the first quarter of 2026.
- Capital spending and liquidity: Capital expenditures are expected at approximately $350 million to $450 million for 2026. The company has $3.5 billion of revolving credit capacity with no borrowings outstanding.
- Patent expiry: Generic entry for Amitiza in Japan may occur in June 2026, depending on patent litigation.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Viatris reported essentially flat total revenues of $3,749.5 million for the third quarter, with a larger net loss of $325.3 million, driven by a higher tax provision. The bigger story is supply: the FDA classified the Nashik, India plant as OAI (a category that can lead to enforcement action), and the company voluntarily suspended production there in October 2026. The company also agreed to buy Pacira for an aggregate equity value of $1.65 billion.
How the business did
- Revenue: Third-quarter total revenues were $3,749.5 million versus $3,759.9 million a year earlier. New product sales of approximately $115.2 million were largely offset by net base business erosion of approximately $126.1 million, tied to supply constraints in Europe and Emerging Markets and added competition. Nine-month revenues were $11,023.3 million versus $10,596.3 million.
- Segments: Greater China net sales rose 14%, helped by e-commerce, retail and hospital channels. Developed Markets fell 2%, JANZ fell 6%, and Emerging Markets fell 7% on lower ARV volumes.
- Profit: Gross margin was 38% versus 36%, and adjusted gross margin (which excludes items such as acquisition-related amortization and restructuring) was approximately 58% versus approximately 56%. Earnings from operations were $261.5 million versus $178.8 million. The net loss widened from $128.2 million as the income tax provision rose to $453.2 million from $120.3 million. Adjusted EPS was $0.71 versus $0.67.
- Cash and capital return: Nine-month operating cash flow was $1.67 billion versus $1.50 billion. The company repurchased approximately $300.0 million of stock and paid $416.9 million in dividends. It ended September with $1.79 billion in cash.
What management is watching
- Plant problems: The Nashik disruption cut third-quarter revenues by approximately $100 million. Management expects a similar hit in the fourth quarter, expects production to resume in the first quarter of 2027, and does not expect to recover the lost 2026 revenue in 2027. At Indore, a warning letter and import alert cover 11 products, and the company anticipates the site will be ready for FDA reinspection in 2026.
- Pacira: The $36.50 per share cash deal is expected to close by the end of November 2026. It will be funded primarily from excess cash, with the remainder from short-term borrowings.
- Restructuring and spending: The company expects total pre-tax charges of between $700 million and $850 million, savings of between $600 million and $700 million once fully implemented, and a workforce reduction of up to approximately 10%. Capital expenditures for 2026 are expected to be approximately $325 million to $400 million.
- Measures cited: Management points to constant currency sales, adjusted gross margin, adjusted EBITDA ($1,195.7 million for the quarter) and adjusted EPS.
New or changed risks
- Deal may not close: The Pacira acquisition requires a majority of Pacira shares to be tendered, expiration of the antitrust waiting period, and no legal restraint. If these are not met, completion could be delayed significantly or prevented.
- Benefits may fall short: Even if the deal closes, underperformance, difficulty integrating the business, or failure to retain Pacira talent could mean the company does not realize the expected benefits, or realizes them on a different timeline.
Follow VTRS in Kortex
The Kortex app shows VTRS's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.